Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE: Acetazolamide to Reduce Weight and Relieve Symptoms in Heart Failure
2025-524344-35-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Montpellier
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of acetazolamide in heart failure (HF) (2 arms), sponsored by Centre Hospitalier Universitaire de Montpellier. Primary endpoint: Primary: Proportion of patients with >2 kg weight loss by Day 5. Planned start Jun 2026; status: authorised.
02
Drugs
acetazolamide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2025-524344-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524344-35-00.